Biochemical acromegaly in patients with prolactinoma during treatment with dopaminergic agonists.

@article{Rosario2010BiochemicalAI,
  title={Biochemical acromegaly in patients with prolactinoma during treatment with dopaminergic agonists.},
  author={Pedro Weslley Rosario and Saulo Purisch},
  journal={Arquivos brasileiros de endocrinologia e metabologia},
  year={2010},
  volume={54 6},
  pages={546-9}
}
OBJECTIVE To evaluate the frequency of subclinical acromegaly (in the absence of clinical phenotype but biochemically uncontrolled) in patients with prolactinoma during treatment with dopaminergic agonists. SUBJECTS AND METHODS One hundred twenty one patients without a phenotype suggestive of acromegaly were studied. RESULTS Initially, the laboratory diagnosis of acromegaly was unequivocal (elevated IGF-1 for gender and age with nadir GH > 1 μg/L) in two patients, and likely (elevated IGF-1… CONTINUE READING